Skip to content

    Cancer Health Center

    Font Size

    Childhood Liver Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (09 / 08 / 2014)

    The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

    General Information

    Added text to state that between 1975 and 2010, childhood cancer mortality decreased by more than 50% (cited Smith et al. as reference 1).

    Added text to state that neonates with hepatoblastoma have comparable outcomes to older children up to age 5 years (cited Trobaugh-Lotrario et al. as reference 13). Also revised text to state that the overall 5-year survival rate is 42% for those with hepatocellular carcinoma.

    Revised Table 1 to include Aicardi syndrome as a disorder associated with hepatoblastoma (cited Kamien et al. as reference 15).

    Added Spector et al. as reference 26.

    Cellular Classification

    Added text to state that fibrolamellar carcinoma histology is characterized by a fusion transcript created by deletion of a 400 kb section of chromosome 19, which was found in 15 of 15 tumors that were tested (cited Honeyman et al. as reference 13).

    Added Weeda et al. reference 18 and level of evidence 3iiA.

    Added Olson et al. as reference 23.

    Stage Information

    Added text to state that revisions and radiologic examples of the PRETEXT staging system were published in 2007 (cited Roebuck et al. as reference 5).

    Treatment Option Overview

    Revised text to state that the International Society of Pediatric Oncology Epithelial Liver Tumor Group (SIOPEL) has reported a pilot study of high-risk hepatoblastoma patients; in SIOPEL-3HR, cisplatin alternating with carboplatin/doxorubicin was administered in a dose intensive fashion. Also added text to state that in a second trial, cisplatin was dose-intensified in a single-arm prospective study; 3-year event-free survival (EFS) was 76% and overall survival (OS) was 83%; toxicity was significant but acceptable (cited 2013 Zsiros et al. as reference 28 and level of evidence 2A).

    Added Antiviral Treatment of Hepatitis B Virus (HBV)-related Hepatocellular Carcinoma as a new subsection.

    Added text to state that chemotherapy followed by transarterial chemoembolization (TACE) followed by high-intensity focused ultrasound showed promising results in China for PRETEXT III and IV patients, some of whom were resectable but did not undergo surgery because of parent refusal (cited Wang et al. as reference 40).

    1 | 2
    Next Article:

    Today on WebMD

    man holding lung xray
    What you need to know.
    stem cells
    How they work for blood cancers.
    woman wearing pink ribbon
    Separate fact from fiction.
    Colorectal cancer cells
    Symptoms, screening tests, and more.
    Jennifer Goodman Linn self-portrait
    what is your cancer risk
    colorectal cancer treatment advances
    breast cancer overview slideshow
    prostate cancer overview
    lung cancer overview slideshow
    ovarian cancer overview slideshow
    Actor Michael Douglas